Captrust Financial Advisors Supernus Pharmaceuticals, Inc. Transaction History

Captrust Financial Advisors

$38.8 Billion
Q1 2025

A detailed history of Captrust Financial Advisors transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 17,731 shares of SUPN stock, worth $570,051. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,731

Previous 17,394 1.94%

Holding current value

$570,051

Previous $628,000 7.64%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$31.17 - $40.0 $10,504 - $13,480	337 Added 1.94%	17,731 $580,000
Q4 2024 Feb 14, 2025	BUY	$31.89 - $37.83 $254,131 - $301,467	7,969 Added 84.55%	17,394 $628,000
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $21,105 - $28,796	-819 Reduced 7.99%	9,425 $293,000
Q2 2024 Aug 14, 2024	SELL	$25.99 - $33.85 $2,261 - $2,944	-87 Reduced 0.84%	10,244 $274,000
Q1 2024 May 15, 2024	BUY	$27.11 - $35.17 $39,960 - $51,840	1,474 Added 16.64%	10,331 $352,000
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $34,125 - $44,579	-1,502 Reduced 14.5%	8,857 $256,000
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $285,597 - $340,914	10,359 New	10,359 $285,000
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $7,300 - $8,784	209 Added 3.46%	6,250 $226,000
Q4 2022 Feb 15, 2023	BUY	$31.09 - $37.88 $3,948 - $4,810	127 Added 2.15%	6,041 $215,000
Q3 2022 Nov 16, 2022	BUY	$28.79 - $35.41 $78,020 - $95,961	2,710 Added 84.58%	5,914 $200,000
Q2 2022 Aug 23, 2022	SELL	$25.33 - $34.25 $911 - $1,233	-36 Reduced 1.11%	3,204 $93,000
Q2 2022 Aug 16, 2022	BUY	$25.33 - $34.25 $6,509 - $8,802	257 Added 8.62%	3,240 $94,000
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $52,743 - $60,865	1,850 Added 163.28%	2,983 $96,000
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $2,399 - $3,114	91 Added 8.73%	1,133 $33,000
Q3 2021 Nov 16, 2021	BUY	$23.54 - $31.39 $3,436 - $4,582	146 Added 16.29%	1,042 $28,000
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $534 - $663	-20 Reduced 2.18%	896 $28,000
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $15,480 - $20,159	641 Added 233.09%	916 $24,000
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $885 - $1,290	50 Added 22.22%	275 $7,000
Q3 2020 Nov 17, 2020	BUY	$20.2 - $25.05 $1,010 - $1,252	50 Added 28.57%	225 $5,000
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $2,990 - $4,355	175 New	175 $4,000
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $2,590 - $3,786	-130 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $3,894 - $5,053	130 New	130 $4,000
Q3 2018 Nov 15, 2018	SELL	$42.7 - $56.55 $640 - $848	-15 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$44.1 - $59.85 $661 - $897	15 New	15 $1,000

Others Institutions Holding SUPN

# of Institutions

305

Shares Held

60.8M

Call Options Held

8.8K

Put Options Held

6.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.72B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Supernus Pharmaceuticals, Inc. Transaction History